Skip to main content
Clinical Trials/NCT05812521
NCT05812521
Completed
Not Applicable

Efficacy of Thoracic Paravertebral Block With Methylene Blue Visual Confirmation in the Management of Postoperative Pain After Video-assisted Thoracoscopic Lobectomy

University of Campania "Luigi Vanvitelli"1 site in 1 country120 target enrollmentJanuary 15, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Post Operative Pain
Sponsor
University of Campania "Luigi Vanvitelli"
Enrollment
120
Locations
1
Primary Endpoint
Change From Baseline in Pain Scores on the Postoperative Numeric Rating Scale in the first 48 hours postoperatively
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The goal of this study is to compare the efficacy in controlling postoperative pain of paravertebral block (PVB) with methylene blue visual confirmation and thoracic epidural anesthesia (TEA). This is a single center, parallel-group, prospective study. Patients will be randomly assigned in a 1:1 ratio to receive either PVB or TEA. Primary end-point is pain relief measured with Postoperative Numeric Rating Scale. The secondary end-points are time to perform TEA and PVB, total opioid consumption, postoperative outcomes.

Detailed Description

The management of postoperative pain in patients undergoing thoracoscopic lobectomy is a fundamental part of the process of recovery. Uncontrolled thoracic pain in the early postoperative period may interfere with the mobilization of the patients, leading to increased morbidity and reduction in the quality of life. Thoracic paravertebral block (PVB) is an effective strategy for controlling postoperative pain after video-assisted thoracoscopic (VATS) lobectomy, but it may be subjected to a high rate of failure due to incorrect identification of the site of local anesthetic injection. Thoracic epidural anesthesia (TEA) is considered a reliable technique for regional thoracic anesthesia, however potential side effects may limit its use. Herein the investigators reported a new technique using methylene blue as a visual confirmation of the correct anesthetic diffusion during PVB. Then, the investigators will compare the efficacy of methylene blue PVB with TEA for the management of postoperative pain in patients undergoing VATS lobectomy. This is a single center, parallel-group, prospective study. Participants will be randomly assigned in a 1:1 ratio to receive either PVB with methylene blue or TEA. All participants will receive postoperatively intravenous acetaminophen as additional analgesics and intravenous tramadol as rescue analgesic. Primary end-point is pain relief measured with Postoperative Numeric Rating Scale at at 1, 12, 24, 48 hours postoperatively. The secondary end-points are: (i) time to perform TEA and PVB, (ii) total opioid consumption, (iii) postoperative outcomes (including complications, chest drainage duration and length of hospital stay).

Registry
clinicaltrials.gov
Start Date
January 15, 2020
End Date
December 16, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Alfonso Fiorelli

Full Professor

University of Campania "Luigi Vanvitelli"

Eligibility Criteria

Inclusion Criteria

  • Males and females aged 18 - 85 years old
  • scheduled to undergo thoracoscopic lobectomy for lung cancer
  • standardized three-port anterior thoracoscopic approach

Exclusion Criteria

  • Allergy to any of the drugs used in the study
  • Previous thoracic surgical procedures or lung resection
  • Psychiatric disorders
  • ASA (American Society of Anesthesiologists) Class \> III
  • Conversion to thoracotomy
  • Lack of written informed consent
  • Participation to other studies
  • Contraindications to epidural analgesia or paravertebral block

Outcomes

Primary Outcomes

Change From Baseline in Pain Scores on the Postoperative Numeric Rating Scale in the first 48 hours postoperatively

Time Frame: 1 hours, 12 hours, 24 hours and 48 hours after surgery

Pain scores at rest and after cough will be evaluated in the first 48 hours postoperatively using Postoperative Numeric Rating Scale (NRS) ranging from 0 (absence of pain) to 10 (maximum level of pain)

Secondary Outcomes

  • Opioids consumption(through the entire hospital stay, an average of 8 days")
  • Time to perform PVB or TEA(From the identification of the site of injection to the start of general anesthesia, up to 1 hour)
  • Chest tube duration(From chest tube placement to chest tube removal, up to 20 days)
  • Length of hospital stay(From hospital admission to discharge, up to 20 days)

Study Sites (1)

Loading locations...

Similar Trials